Clinical trials: IV Access
Cancer
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection.
- Trial name
- NCT00378781
- Testing
- Heparin, Minocycline-EDTA
- Sponsor
- M.D. Anderson Cancer Center
ALK Positive Malignancies
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
The rollover study will provide ceritinib to patients who are currently receiving treatment with ceritinib within a Novartis-sponsored study and in the opinion of the investigator, would benefit from continued treatment with…
- Trial name
- NCT02584933
- Testing
- ceritinib
- Where
- 71 sites in United States, Australia and 19 more
- Volunteers
- 233 people
- Sponsor
- Novartis Pharmaceuticals
Radiology
VR to Reduce Pain/Anxiety During IV Starts
This study aims to test the effectiveness of virtual reality (VR) as a non-pharmaceutical intervention to reduce pain and anxiety in children undergoing peripheral intravenous catheter (PIVC) access in the Department of Radiology…
- Trial name
- NCT04942561
- Testing
- Samsung Gear VR, Merge VR
- Where
- United States
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Los Angeles
Unsafe Sex, IV Drug Usage
Evaluation of Implementation of the Phoenix PrEP (Pre-Exposure Prophylaxis) Access Project for Youth Aged 13-24
This study will evaluate the implementation of a PrEP program for youth aged 13-24 in Phoenix, AZ. Numbers of youth who initiate PrEP, how long they continue with PrEP, and the barriers for youth who are trying to initiate and…
- Trial name
- NCT03637322
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Phoenix Children's Hospital
Mucopolysaccharidosis IVA, Morquio A Syndrome
BMN 110 US Expanded Access Program
The Expanded Access Program (EAP) is an open-label, multicenter program to: 1. Provide patients who have been diagnosed with Mucopolysaccharidosis IVA (MPS IVA) access to BMN 110 until commercial product is available 2.
- Conditions
- Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
- Trial name
- NCT01858103
- Testing
- BMN 110
- Where
- 25 sites in United States, Puerto Rico
- Sponsor
- BioMarin Pharmaceutical
Pain on IV Injection of Propofol.
Combining Placing a Synera Patch With Propofol/Lidocaine Mixture to Decrease Pain With IV Propofol Injection
The main objective is to evaluate if combining placing the Synera patch and using Propofol /Lidocaine mixture will further decrease the pain associated with the IV injection of Propofol.
- Trial name
- NCT02240628
- Testing
- Lidocaine/tetracaine transdermal patch, Saline, Lidocaine
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Intravenous Access
Effect of Passive Leg Raise for Pediatric Peripheral IV Placement
The investigators wish to determine whether passive leg raise allows for easier peripheral vascular access in the pediatric population.
- Trial name
- NCT03029754
- Testing
- Passive leg raise
- Where
- Canada
- Volunteers
- 87 people
- Sponsor
- University of Saskatchewan
Catheterization, Peripheral Phlebotomy
Variation In Success of Intravenous (IV) Placement With Observation Using New Techniques
Children fear having an intravenous (IV) needle placed because of the pain that they will experience. The more needle punctures that a child has to endure before the IV is successfully placed, the greater the pain experienced and…
- Trial name
- VISION (NCT01133652)
- Testing
- Veinviewer, Ultrasound, Conventional technique
- Where
- Canada
- Volunteers
- 399 people
- Sponsor
- University of Alberta
Melanoma
Compassionate Use Trial for Unresectable Melanoma With Ipilimumab
The primary objective of the study is to provide treatment with Ipilimumab to subjects who have serious or immediately life-threatening unresectable Stage III or Stage IV melanoma, who have no alternative treatment options, and…
- Trial name
- NCT00495066
- Testing
- Ipilimumab
- Where
- 9 sites in Brazil
- Sponsor
- Bristol-Myers Squibb
Non Small Cell Lung Cancer
Nivolumab in the Real World: Analysis of the Expanded Use in Spanish Patient
The investigators will be retrospectively review the case note of patients registered in the EAP of Nivolumab. A standard anonymous data collection form will be used to collect data and to analyze it.
- Trial name
- NIVEX (NCT03132493)
- Testing
- Nivolumab 10 MG/ML
- Where
- 61 sites in Spain
- Volunteers
- 676 people
- Sponsor
- Spanish Lung Cancer Group
Pediatric Disorder
A Comparison of Accuvein to Standard IV Access in Children 0 to 24 Months of Age in the Pediatric ED
Obtaining intravenous (IV) access in children under the age of 2 years is difficult, especially in the emergency department (ED) where the children can be frightened, dehydrated and ill.
- Trial name
- NCT02381392
- Testing
- Accuvein AV400
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Total Parenteral Nutrition-induced Cholestasis
Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD
This is an expanded access protocol for use of intravenous fish oil infusion, Omegaven, in infants and children with parenteral nutrition associated liver disease (PNALD) to decrease elevated liver enzymes and direct bilirubin.
- Trial name
- NCT02929303
- Testing
- Omegaven IV lipid emulsion
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Neuroblastoma, Childhood Metastatic Pheochromocytoma
131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol
Metaiodobenzylguanidine (MIBG) is a substance that is taken up by neuroblastoma cells. MIBG is combined with radioactive iodine (131 I) in the laboratory to form a radioactive compound 131 I-MIBG.
- Trial name
- NCT01163383
- Testing
- 131 I-Metaiodobenzylguanidine (131 I-MIBG), 131 I-MIBG
- Where
- United States
- Sponsor
- John Maris
Intravenous Access According to Instructions For Use
Study Comparing the Handling of Two Peripheral IV Catheter Systems
A peripheral intravenous catheter is the most commonly used vascular access device in medicine. Primary objective is to compare insertion and handling of two peripheral intravenous catheters in clinical routine.
- Trial name
- NCT02213965
- Testing
- Peripheral IV catheter
- Where
- 2 sites in Germany
- Volunteers
- 2,340 people
- Sponsor
- B. Braun Melsungen AG
Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are Unable to Receive Intravenous (IV) Daratumumab
The purpose of this pre-approval access (PAA) program is to provide treatment to participants with serious/life-threatening diseases or conditions.
- Trial name
- NCT04264884
- Testing
- Daratumumab
- Sponsor
- Janssen Research & Development, LLC
Acute Pain, Procedural Anxiety
Little NIRVANA for Pediatric Pain and Anxiety
The aim of this study is to test the feasibility of using Little NIRVANA (augmented reality (AR)) for managing anxiety and pain for children 2-8 years old during hospital emergency peripheral intravenous (PIV) insertions.
- Conditions
- Acute Pain, Procedural Anxiety, Pediatric ALL, Emergency Medicine
- Trial name
- NCT06795126
- Testing
- Little NIRVANA
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Nationwide Children's Hospital
Steroid Resistant Acute Graft Versus Host Disease
Early Access Program With Inolimomab in Steroid-refractory Acute Graft Versus Host Disease
Leukotac (inolimomab) is not approved yet for marketing in any region. In the absence of medical options and based on the safety and efficacy data obtained during the clinical development program (in a phase III (INO-107) and in…
- Trial name
- NCT05047328
- Testing
- inolimomab
- Where
- France
- Sponsor
- ElsaLys Biotech
Difficult Intravenous Access in Pediatrics
Ultrasound Guided IV Access in a Pediatric Emergency Department
The primary objective is to determine whether the use of ultrasound guidance compared to standard IV access improves the proportion of successful IV placement on a first attempt for children in a pediatric emergency department…
- Trial name
- USgIV (NCT02125552)
- Testing
- Ultrasound guidance, Traditional intravenous access
- Where
- United States
- Volunteers
- 163 people
- Sponsor
- Children's Hospital of Philadelphia
Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer
Physicians interested in requesting a single patient IND should contact Seattle Genetics' Medical Information (medinfo@seagen.com).
- Trial name
- NCT03424473
- Testing
- Tucatinib
- Sponsor
- Seagen Inc.
Cervical Cancer, Endometrial Cancer
Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Conditions
- Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Neurotoxicity
- Trial name
- NCT00003624
- Testing
- amifostine trihydrate, cisplatin, paclitaxel
- Where
- 8 sites in United States
- Sponsor
- Gynecologic Oncology Group